Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

NCT01560663 · clinicaltrials.gov ↗

UNKNOWN

Status

415

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Cancer Stage II-III

Interventions

DRUG: Docetaxel- Carboplatin

Sponsor

Miguel Martín Jiménez

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]